Eton Pharmaceuticals (ETON) News Today $16.97 -0.37 (-2.13%) Closing price 05/5/2025 04:00 PM EasternExtended Trading$17.00 +0.04 (+0.21%) As of 04:34 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Shares Purchased by Marshall Wace LLPMarshall Wace LLP grew its position in Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) by 75.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 36,182 shares of the company's stock after purchasing an additionMay 5 at 3:35 AM | marketbeat.com683 Capital Management LLC Purchases New Shares in Eton Pharmaceuticals, Inc. (NASDAQ:ETON)683 Capital Management LLC acquired a new position in shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 69,000 shares of the company's stMay 4 at 7:14 AM | marketbeat.comEton Pharmaceuticals (ETON) to Release Quarterly Earnings on ThursdayEton Pharmaceuticals (NASDAQ:ETON) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 8. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-8-eton-pharmaceuticals-inc-stock/)May 3 at 4:45 AM | marketbeat.comQ1 EPS Estimate for Eton Pharmaceuticals Lifted by AnalystEton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) - Equities research analysts at B. Riley lifted their Q1 2025 earnings estimates for Eton Pharmaceuticals in a research note issued on Sunday, April 27th. B. Riley analyst M. El-Saadi now expects that the company will earn $0.13 per share forMay 2, 2025 | marketbeat.comJPMorgan Chase & Co. Acquires 51,238 Shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON)JPMorgan Chase & Co. raised its stake in Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) by 7,086.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 51,961 shares of the company's stock after buying an addMay 2, 2025 | marketbeat.comEton Pharmaceuticals to Report First Quarter 2025 Financial Results on Tuesday, May 13, 2025May 1, 2025 | globenewswire.comB. Riley Lifts Earnings Estimates for Eton PharmaceuticalsEton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) - Equities researchers at B. Riley upped their Q4 2025 earnings per share estimates for Eton Pharmaceuticals in a report released on Sunday, April 27th. B. Riley analyst M. El-Saadi now forecasts that the company will post earnings of $0.33 pMay 1, 2025 | marketbeat.comB. Riley Raises Earnings Estimates for Eton PharmaceuticalsMay 1, 2025 | americanbankingnews.comQ1 EPS Estimate for Eton Pharmaceuticals Boosted by AnalystMay 1, 2025 | americanbankingnews.comNantahala Capital Management LLC Grows Stock Holdings in Eton Pharmaceuticals, Inc. (NASDAQ:ETON)Nantahala Capital Management LLC boosted its position in Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) by 12.0% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 1,118,483 shares of the company's stock after acquiring an additional 119,750 shares during tApril 30, 2025 | marketbeat.comEton Pharmaceuticals Announces Submission of NDA for ET-600 (Desmopressin Oral Solution)April 28, 2025 | globenewswire.com24,710 Shares in Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Bought by Jump Financial LLCJump Financial LLC acquired a new stake in Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 24,710 shares of the company's stock, valued at approximately $329,000.April 28, 2025 | marketbeat.comRenaissance Technologies LLC Has $2.57 Million Holdings in Eton Pharmaceuticals, Inc. (NASDAQ:ETON)Renaissance Technologies LLC grew its position in shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) by 131.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 193,100 shares of the company's stock after bApril 27, 2025 | marketbeat.comEton Pharmaceuticals, Inc. (NASDAQ:ETON) Short Interest UpdateEton Pharmaceuticals, Inc. (NASDAQ:ETON - Get Free Report) was the recipient of a large growth in short interest during the month of March. As of March 31st, there was short interest totalling 343,900 shares, a growth of 46.0% from the March 15th total of 235,600 shares. Based on an average trading volume of 287,400 shares, the short-interest ratio is presently 1.2 days. Currently, 1.6% of the company's shares are short sold.April 20, 2025 | marketbeat.comEAM Investors LLC Decreases Stake in Eton Pharmaceuticals, Inc. (NASDAQ:ETON)EAM Investors LLC trimmed its position in shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) by 25.9% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 95,019 shares of the company's stock after selling 33,257 shares during the periodApril 19, 2025 | marketbeat.comB.Riley Financial Remains a Buy on Eton Pharmaceuticals (ETON)April 17, 2025 | markets.businessinsider.comEton Pharmaceuticals management to meet virtually with B. RileyApril 12, 2025 | markets.businessinsider.comEton Pharmaceuticals management to meet with Craig HallumApril 10, 2025 | markets.businessinsider.comCannell Capital LLC Purchases New Shares in Eton Pharmaceuticals, Inc. (NASDAQ:ETON)Cannell Capital LLC bought a new stake in Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 381,323 shares of the company's stock, valued at approximatelyApril 10, 2025 | marketbeat.comAristides Capital LLC Grows Stock Holdings in Eton Pharmaceuticals, Inc. (NASDAQ:ETON)Aristides Capital LLC raised its stake in Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) by 20.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 241,587 shares of the company's stocApril 8, 2025 | marketbeat.comEton Pharmaceuticals out-licenses international rights to IncrelexApril 2, 2025 | markets.businessinsider.comCraig-Hallum Sticks to Their Buy Rating for Eton Pharmaceuticals (ETON)April 2, 2025 | markets.businessinsider.comEton Pharmaceuticals, Inc. (NASDAQ:ETON) Sees Significant Drop in Short InterestEton Pharmaceuticals, Inc. (NASDAQ:ETON - Get Free Report) was the recipient of a significant decline in short interest in March. As of March 15th, there was short interest totalling 235,600 shares, a decline of 18.6% from the February 28th total of 289,400 shares. Based on an average daily volume of 278,300 shares, the days-to-cover ratio is presently 0.8 days. Currently, 1.1% of the company's stock are sold short.April 2, 2025 | marketbeat.comESTEVE signs a licensing agreement for a severe primary insulin-like growth factor 1 deficiency treatmentApril 1, 2025 | finance.yahoo.comEton sells ex-U.S. rights for hormone disorder therapy to Esteve PharmaApril 1, 2025 | msn.comEton Pharmaceuticals Out-Licenses International Rights to Increlex®April 1, 2025 | globenewswire.comHillsdale Investment Management Inc. Invests $226,000 in Eton Pharmaceuticals, Inc. (NASDAQ:ETON)Hillsdale Investment Management Inc. acquired a new stake in Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 17,003 shares of the company's stock, valuedMarch 25, 2025 | marketbeat.comCROSSJECT updates on its collaboration with ETON PHARMACEUTICALS, Inc. and the ZENEO® adrenal insufficiency programMarch 25, 2025 | globenewswire.comB. Riley Equities Analysts Raise Earnings Estimates for ETONEton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) - Equities researchers at B. Riley increased their Q3 2025 earnings estimates for Eton Pharmaceuticals in a note issued to investors on Wednesday, March 19th. B. Riley analyst M. El-Saadi now anticipates that the company will post earnings peMarch 22, 2025 | marketbeat.comQ2 EPS Estimate for Eton Pharmaceuticals Lowered by AnalystEton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) - Stock analysts at HC Wainwright cut their Q2 2025 earnings estimates for shares of Eton Pharmaceuticals in a research note issued to investors on Wednesday, March 19th. HC Wainwright analyst S. Ramakanth now anticipates that the company wilMarch 22, 2025 | marketbeat.comQ1 EPS Estimates for Eton Pharmaceuticals Lifted by B. RileyEton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) - Equities researchers at B. Riley increased their Q1 2025 EPS estimates for Eton Pharmaceuticals in a report issued on Wednesday, March 19th. B. Riley analyst M. El-Saadi now expects that the company will post earnings of $0.06 per share forMarch 21, 2025 | marketbeat.comEton Pharmaceuticals (NASDAQ:ETON) Stock Price Expected to Rise, Craig Hallum Analyst SaysCraig Hallum raised their price objective on shares of Eton Pharmaceuticals from $23.00 to $26.00 and gave the company a "buy" rating in a research note on Wednesday.March 20, 2025 | marketbeat.comEton Pharmaceuticals' (ETON) "Buy" Rating Reiterated at B. RileyB. Riley restated a "buy" rating and set a $24.00 price target (up from $21.00) on shares of Eton Pharmaceuticals in a research report on Wednesday.March 20, 2025 | marketbeat.comEton Pharmaceuticals (NASDAQ:ETON) Given Buy Rating at HC WainwrightHC Wainwright restated a "buy" rating and issued a $33.00 target price on shares of Eton Pharmaceuticals in a report on Wednesday.March 20, 2025 | marketbeat.comEton Pharmaceuticals price target raised to $26 from $23 at Craig-HallumMarch 19, 2025 | markets.businessinsider.comEton Pharmaceuticals price target raised to $24 from $21 at B. RileyMarch 19, 2025 | markets.businessinsider.comEton Pharmaceuticals, Inc. (NASDAQ:ETON) Short Interest Down 18.0% in FebruaryEton Pharmaceuticals, Inc. (NASDAQ:ETON - Get Free Report) was the recipient of a large decrease in short interest in February. As of February 28th, there was short interest totalling 289,400 shares, a decrease of 18.0% from the February 13th total of 353,000 shares. Based on an average daily trading volume, of 263,000 shares, the days-to-cover ratio is presently 1.1 days. Approximately 1.3% of the company's shares are short sold.March 19, 2025 | marketbeat.com5 Analysts Assess Eton Pharmaceuticals: What You Need To KnowMarch 19, 2025 | benzinga.comEton Pharmaceuticals Full Year 2024 Earnings: Revenues Beat Expectations, EPS LagsMarch 19, 2025 | finance.yahoo.comEton Pharmaceuticals, Inc. (NASDAQ:ETON) Q4 2024 Earnings Call TranscriptMarch 19, 2025 | insidermonkey.comEton Pharmaceuticals (NASDAQ:ETON) Announces Quarterly Earnings ResultsEton Pharmaceuticals (NASDAQ:ETON - Get Free Report) issued its earnings results on Tuesday. The company reported ($0.02) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.02). Eton Pharmaceuticals had a negative return on equity of 36.29% and a negative net margin of 15.81%.March 19, 2025 | marketbeat.comEton Pharmaceuticals reports Q4 EPS (2c), consensus 0cMarch 18, 2025 | markets.businessinsider.comEton Pharmaceuticals, Inc. (ETON) Virtual Investor Day and Q4 2024 Earnings Call TranscriptMarch 18, 2025 | seekingalpha.comEton Pharmaceuticals Reports Fourth Quarter 2024 Financial ResultsMarch 18, 2025 | globenewswire.comEton Pharmaceuticals, Inc. (NASDAQ:ETON) Shares Purchased by Connor Clark & Lunn Investment Management Ltd.Connor Clark & Lunn Investment Management Ltd. grew its position in Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) by 230.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 214,878 shares of the comMarch 18, 2025 | marketbeat.comEton Pharmaceuticals reports ‘positive’ data from study of ET-600March 14, 2025 | markets.businessinsider.comEton Pharmaceuticals Announces Positive Pivotal Clinical Study Results for Product Candidate ET-600March 14, 2025 | globenewswire.comEton Pharmaceuticals (ETON) to Release Earnings on ThursdayEton Pharmaceuticals (NASDAQ:ETON) will be releasing earnings before the market opens on Thursday, March 13, Financial Modeling Prep reports.March 6, 2025 | marketbeat.comOptime Care Partners with Eton Pharmaceuticals as a Specialty Pharmacy Provider for GALZIN®March 4, 2025 | globenewswire.comEton Pharmaceuticals to Host Virtual Investor Day and Release Fourth Quarter Earnings Results on March 18, 2025March 4, 2025 | globenewswire.com Get Eton Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ETON and its competitors with MarketBeat's FREE daily newsletter. Email Address ETON Media Mentions By Week ETON Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ETON News Sentiment▼0.900.72▲Average Medical News Sentiment ETON News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ETON Articles This Week▼163▲ETON Articles Average Week Get Eton Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ETON and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies APGE News AGIO News HRMY News EWTX News IRON News INDV News KNSA News ANIP News IMCR News EVO News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ETON) was last updated on 5/6/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredMost traders are panicking. We’re cashing inMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredTrump’s Bitcoin Reserve is No Accident…Crypto policy is changing fast… Smart investors are positioning themselves to benefit. And it's all happeni...Crypto 101 Media | SponsoredElon Musk is all in on these robots …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eton Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eton Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.